Sorafenib for Advanced and Refractory Desmoid Tumors

Sorafenib for Advanced and Refractory Desmoid Tumors

Desmoid tumors are rare and difficult to treat. This trial of daily sorafenib versus placebo documented an objective response rate of 33% with sorafenib and 20% with placebo. The 2-year progression-free survival rate was 81% with sorafenib and 36% with placebo.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2018-12, Vol.379 (25), p.2417-2428
Hauptverfasser: Gounder, Mrinal M, Mahoney, Michelle R, Van Tine, Brian A, Ravi, Vinod, Attia, Steven, Deshpande, Hari A, Gupta, Abha A, Milhem, Mohammed M, Conry, Robert M, Movva, Sujana, Pishvaian, Michael J, Riedel, Richard F, Sabagh, Tarek, Tap, William D, Horvat, Natally, Basch, Ethan, Schwartz, Lawrence H, Maki, Robert G, Agaram, Narasimhan P, Lefkowitz, Robert A, Mazaheri, Yousef, Yamashita, Rikiya, Wright, John J, Dueck, Amylou C, Schwartz, Gary K
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Aged
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biomarkers
Biopsy
Cancer therapies
Clinical trials
Computer centers
Diarrhea
Double-Blind Method
Fatigue
Female
Fibromatosis, Aggressive - drug therapy
Fibromatosis, Aggressive - mortality
Follow-Up Studies
Gene expression
Grants
Growth factors
Humans
Inhibitor drugs
Kaplan-Meier Estimate
Kinases
Laboratories
Male
Medical imaging
Medical research
Mesentery
Middle Aged
Mutation
Neoplasia
NMR
Nuclear magnetic resonance
Oncology
Progression-Free Survival
Sorafenib - adverse effects
Sorafenib - therapeutic use
Survival
Survival Rate
Targeted cancer therapy
Tumors
Young Adult
Young adults
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Desmoid tumors are rare and difficult to treat. This trial of daily sorafenib versus placebo documented an objective response rate of 33% with sorafenib and 20% with placebo. The 2-year progression-free survival rate was 81% with sorafenib and 36% with placebo.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1805052